Factor V11 or factor V11A GLA domain variants
View Patent ↗Gla domain variants of human Factor VII or human Factor VIIa, comprising 1-15 amino acid modifications relative to human Factor VII or human Factor VIIa, wherein a hydrophobic amino acid residue has been introduced by substitution in position 34 or having an amino acid substitution in position 36 of the amino acid sequence shown in SEQ ID NO:1; and use of the variants for the treatment of intracerebral haemorrhage (ICH) or trauma.
1. A method for treating a mammal having a disease or a disorder wherein blood clot formation is desirable, comprising administering to a mammal in need thereof an effective amount of a recombinant Factor VII (FVII) or Factor VIIa (FVIIa) polypeptide variant, said variant comprising the amino acid sequence shown in SEQ ID NO:1 with six amino acid substitutions, said six amino acid substitutions consisting of a glutamic acid residue substituted for the arginine residue in position 36, a glutamine residue substituted for the proline residue in position 10, a glutamic acid residue substituted for the lysine residue in position 32, a glutamic acid residue substituted for the alanine residue in position 34, an asparagine residue substituted for the threonine residue in position 106, and an asparagine residue substituted for the valine residue in position 253 of SEQ ID NO:1, wherein said disease or disorder is selected from the group consisting of a hemorrhage, gastrointestinal bleeding, uncontrolled bleeding, bleeding in a mammal undergoing transplantation or resection or surgery, variceal bleeding, thrombocytopenia and hemophilia.
2. The method of claim 1 , wherein said disease or disorder is bleeding due to trauma.
3. The method of claim 2 , wherein said trauma is blunt trauma.
4. The method of claim 2 , wherein said trauma is penetrative trauma.
5. The method of claim 2 , wherein the mammal is a human.
6. The method of claim 1 , wherein said disease or disorder is hemophilia.
7. The method of claim 6 , wherein the mammal is a human.
8. The method of claim 1 , wherein said uncontrolled bleeding is severe uncontrolled bleeding.
9. The method of claim 8 , wherein the mammal is a human.
10. The method of claim 1 , wherein said disease or disorder is bleeding in surgery.
11. The method of claim 1 , wherein said disease or disorder is thrombocytopenia.
12. The method of claim 1 , wherein said hemorrhage is a brain hemorrhage.
13. The method of claim 1 , wherein the mammal is a human.
14. A method for treating intracerebral haemorrhage or traumatic brain injury, comprising administering to a mammal in need thereof an effective amount of a recombinant Factor VII (FVII) or Factor VIIa (FVIIa) polypeptide variant, said variant comprising the amino acid sequence shown in SEQ ID NO:1 with six amino acid substitutions, said six amino acid substitutions consisting of a glutamic acid residue substituted for the arginine residue in position 36, a glutamine residue substituted for the proline residue in position 10, a glutamic acid residue substituted for the lysine residue in position 32, a glutamic acid residue substituted for the alanine residue in position 34, an asparagine residue substituted for the threonine residue in position 106, and an asparagine residue substituted for the valine residue in position 253 of SEQ ID NO:1.
15. The method of claim 14 , wherein the mammal is a human.
16. A method for treating a mammal having a disease or disorder wherein blood clot formation is desirable, said method comprising administering to a mammal in need thereof an effective amount of a conjugate comprising:
(1) a recombinant Factor VII (FVII) or Factor VIIa (FVIIa) polypeptide variant and a sugar moiety, wherein the polypeptide variant comprises the amino acid sequence shown in SEQ ID NO:1 with six amino acid substitutions, said six amino acid substitutions consisting of a glutamic acid residue substituted for the arginine residue in position 36, a glutamine residue substituted for the proline residue in position 10, a glutamic acid residue substituted for the lysine residue in position 32, a glutamic acid residue substituted for the alanine residue in position 34, an asparagine residue substituted for the threonine residue in position 106, and an asparagine residue substituted for the valine residue in position 253 of SEQ ID NO:1; and
(2) a sugar moiety covalently attached to the asparagine residue in position 106 or position 253 of the amino acid sequence of the polypeptide variant,
wherein said disease or disorder is selected from the group consisting of a hemorrhage, gastrointestinal bleeding, uncontrolled bleeding, bleeding in a mammal undergoing transplantation or resection or surgery, variceal bleeding, thrombocytopenia and hemophilia.
17. The method of claim 16 , wherein the sugar moiety is covalently attached to each of the asparagine residues in position 106 and 253 of the amino acid sequence of the polypeptide variant.
18. The method of claim 16 , the method comprising administering to a mammal in need thereof an effective amount of said recombinant FVIIa polypeptide variant.
19. The method of claim 16 , wherein the mammal is a human.